@article{KelmReibetanzKimetal.2022,
  author    = {Kelm, Matthias and Reibetanz, Joachim and Kim, Mia and Schoettker, Kathrin and Brand, Markus and Meining, Alexander and Germer, Christoph-Thomas and Flemming, Sven},
  title     = {Kono-S anastomosis in Crohn's disease: A retrospective study on postoperative morbidity and disease recurrence in comparison to the conventional side-to-side anastomosis},
  series = {Journal of Clinical Medicine},
  volume    = {11},
  journal   = {Journal of Clinical Medicine},
  number    = {23},
  issn      = {2077-0383},
  doi       = {10.3390/jcm11236915},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-297334},
  year      = {2022},
  abstract  = {Introduction: The rates of postoperative recurrence following ileocecal resection due to Crohn's disease remain highly relevant. Despite this fact, while the Kono-S anastomosis technique initially demonstrated promising results, robust evidence is still lacking. This study aimed to analyze the short- and long-term outcomes of the Kono-S versus side-to-side anastomosis. Methods: A retrospective single-center study was performed including all patients who received an ileocecal resection between 1 January 2019 and 31 December 2021 at the Department of Surgery at the University Hospital of Wuerzburg. Patients who underwent conventional a side-to-side anastomosis were compared to those who received a Kono-S anastomosis. The short- and long-term outcomes were analyzed for all patients. Results: Here, 29 patients who underwent a conventional side-to-side anastomosis and 22 patients who underwent a Kono-S anastomosis were included. No differences were observed regarding short-term postoperative outcomes. The disease recurrence rate postoperatively was numerically lower following the Kono-S anastomosis (median Rutgeert score of 1.7 versus 2.5), with a relevantly increased rate of patients in remission (17.2\% versus 31.8\%); however, neither of these results reached statistical significance. Conclusion: The Kono-S anastomosis method is safe and feasible and potentially decreases the severity of postoperative disease remission.},
  language  = {en}
}
@article{KelmAngerEichlingeretal.2021,
  author    = {Kelm, Matthias and Anger, Friedrich and Eichlinger, Robin and Brand, Markus and Kim, Mia and Reibetanz, Joachim and Krajinovic, Katica and Germer, Christoph-Thomas and Schlegel, Nicolas and Flemming, Sven},
  title     = {Early Ileocecal Resection Is an Effective Therapy in Isolated Crohn's Disease},
  series = {Journal of Clinical Medicine},
  volume    = {10},
  journal   = {Journal of Clinical Medicine},
  number    = {4},
  issn      = {2077-0383},
  doi       = {10.3390/jcm10040731},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-228822},
  year      = {2021},
  abstract  = {Despite the increasing incidence and prevalence of Crohn's Disease (CD), no curative options exist and treatment remains complex. While therapy has mainly focused on medical approaches in the past, growing evidence reveals that in cases of limited inflammation, surgery can suffice as an alternative primary treatment. We retrospectively assessed the disease course and outcomes of 103 patients with terminal Ileitis who underwent primary surgery (n = 29) or received primary medical treatment followed by surgery (n = 74). Primary endpoint was the need for immunosuppressive medication after surgical treatment (ileocecal resection, ICR) during a two-years follow-up. Rates for laparoscopic ICR were enhanced in case of early surgery, but no differences were seen for postoperative complications. In case of immunosuppressive medication, patients with ICR at an early state of disease needed significantly less anti-inflammatory medication during the two-year postoperative follow-up compared to patients who were primarily treated medically. Furthermore, in a subgroup analysis for patients with localized ileocecal disease manifestation, early surgery consistently resulted in a decreased amount of medical therapy postoperatively. In conclusion primary ICR is safe and effective in patients with limited CD, and the need for immunosuppressive medication during the postoperative follow-up is low compared to patients receiving surgery at a later stage of disease.},
  language  = {en}
}